We are live on ! Find out more
DSGN icon

Design Therapeutics
DSGN

95 hedge funds and large institutions have $108M invested in Design Therapeutics in 2024 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 27 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 27

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

2.42% more ownership

Funds ownership: 54.39% → 56.81% (+2.4%)

2% more funds holding

Funds holding: 93 → 95 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

13% less capital invested

Capital invested by funds: $124M → $108M (-$16.4M)

93% less call options, than puts

Call options by funds: $5K | Put options by funds: $75K

Holders
95
Holders Change
+2
Holders Change %
+2.15%
% of All Funds
1.37%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
15
Increased
36
Reduced
27
Closed
13
Calls
$5K
Puts
$75K
Net Calls
-$70K
Net Calls Change
-$56K

Top Buyers

Rank Fund Capital Flow
1
FLSM
Frazier Life Sciences Management
California
+$4.66M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.55M
3
AC
Almitas Capital
California
+$885K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$700K
5
Millennium Management
Millennium Management
New York
+$492K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$2.22M
2
BCM
BML Capital Management
Indiana
-$1.78M
3
Walleye Capital
Walleye Capital
New York
-$523K
4
SC
Shay Capital
New York
-$517K
5
Morgan Stanley
Morgan Stanley
New York
-$345K
Name Holding Trade Value Shares
Change 		Change in
Stake
SOCM
1
SR One Capital Management
Pennsylvania
$21.9M – – –
LGM
2
Logos Global Management
California
$16.9M – – –
BlackRock
3
BlackRock
New York
$7.72M +$120K +30,757 +1%
BBA
4
Baker Bros. Advisors
New York
$5.68M +$129K +33,174 +2%
TCM
5
Tang Capital Management
California
$4.96M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$4.34M +$42.2K +10,826 +0.8%
AC
7
Almitas Capital
California
$4.2M +$885K +227,180 +22%
FLSM
8
Frazier Life Sciences Management
California
$4M +$4.66M +1,195,179 New
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$3.32M +$1.55M +397,285 +67%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$2.37M +$93.8K +24,073 +4%
State Street
11
State Street
Massachusetts
$2.33M -$13.9K -3,563 -0.5%
Millennium Management
12
Millennium Management
New York
$2.05M +$492K +126,335 +26%
Goldman Sachs
13
Goldman Sachs
New York
$2.02M +$380K +97,449 +19%
Acadian Asset Management
14
Acadian Asset Management
Massachusetts
$1.95M +$700K +179,614 +45%
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$1.79M +$349K +89,594 +20%
Jacobs Levy Equity Management
16
Jacobs Levy Equity Management
New Jersey
$1.6M -$100K -25,762 -5%
BCM
17
BML Capital Management
Indiana
$1.41M -$1.78M -457,729 -52%
Two Sigma Investments
18
Two Sigma Investments
New York
$1.35M -$75.3K -19,320 -5%
Two Sigma Advisers
19
Two Sigma Advisers
New York
$1.34M -$15.2K -3,900 -1%
Morgan Stanley
20
Morgan Stanley
New York
$1.3M -$345K -88,655 -19%
Renaissance Technologies
21
Renaissance Technologies
New York
$1.29M -$270K -69,325 -15%
Assenagon Asset Management
22
Assenagon Asset Management
Luxembourg
$1.17M – – –
PGCM
23
Prescott Group Capital Management
Oklahoma
$1.15M – – –
Northern Trust
24
Northern Trust
Illinois
$1.13M -$77.7K -19,939 -6%
Citadel Advisors
25
Citadel Advisors
Florida
$1.02M -$2.22M -570,147 -65%
1
2 3 4 5

DSGN Hedge Fund Activity: Q2 2024 in Review

95 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q2 2024, worth a combined $108M — down 13% from $124M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new DSGN positions and 13 closed out — a net gain of 2 holders — while 36 added to existing stakes and 27 trimmed.

The largest buyer was Frazier Life Sciences Management, opening a new position worth an estimated $4.66M. The largest seller was Citadel Advisors, cutting an estimated $2.22M.

  • 95 institutional investors held Design Therapeutics (DSGN) as of Q2 2024, up from 93 in Q1 2024.
  • Funds reported $108M of Design Therapeutics stock for Q2 2024, down 13% quarter-over-quarter.
  • 15 funds opened new Design Therapeutics positions in Q2 2024 and 13 closed out, a net change of +2 holders.
  • The largest Design Therapeutics buyer in Q2 2024 was Frazier Life Sciences Management, an estimated $4.66M added.
  • The largest Design Therapeutics seller in Q2 2024 was Citadel Advisors, an estimated $2.22M sold.

Based on aggregated 13F filings for Q2 2024.